Skip to content
DataLookout
Menu

NCT07941531

T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Nov 18, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.

All 1 version: 1 with changes below. See every version on ClinicalTrials.gov ↗

  1. Study First Submitted

Endpoints

Primary

Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm A)
Timeframe: up to 4 weeks after CD7CAR T-cell infusion
Maximum Tolerated Dose (MTD) of CD7-CAR T cells (Arm B)
Timeframe: up to 4 weeks after CD7CAR T-cell infusion

Arms and interventions

Arm AExperimental

patients will receive autologous CD7-CAR T-cells

Arm BExperimental

Patients will receive lymphodepleting chemotherapy (Cy/Flu), followed by an infusion of CD7-CAR T cells.

Drugs: Fludarabine, Cyclophosphamide, Mesna

Devices: CliniMACS

Sites

1 site in 1 country

  • St. Jude Children's Research HospitalMemphis, Tennessee, United States